Arzerra (ofatumumab) - Novartis, Genmab
Case report of anti-vimentin IgG-associated autoimmune encephalitis: diagnostic challenges and the role of 18F-DPA714 PET/MRI. (PubMed, BMJ Neurol Open) - Oct 3, 2026 - "After intravenous immunoglobulin induction and ofatumumab maintenance therapy, the patient showed clinical improvement (modified Rankin Scale from 2 to 1) at 3-month follow-up, paralleled by reduced tracer uptake. This first reported middle-aged male case expands the demographic and phenotypic spectrum of anti-vimentin IgG-associated AE to include PNS involvement. This case highlights the diagnostic value of antibody detection and advanced imaging modalities in atypical presentations of anti-vimentin IgG-associated AE." 
Journal • Ataxia • CNS Disorders • Immunology • Inflammation • Movement Disorders • Pain • VIM
http://www.ncbi.nlm.nih.gov/pubmed/42825263
 
Huanyu Meng; Sheng Chen; Siqi Tu; Siyu Dong
 
Oct 3, 2026
 
Prev Next